At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 229 enrolled
Drug / intervention
Technosphere® Insulin Inhalation Powder and MedTone™ Inhalerdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Four-year, Safety and Tolerability, Open-Label, "Follow on" Trial Evaluating Technosphere® Insulin in Subjects With Type 2 Diabetes Mellitus.
In Brief
A Phase 2 clinical trial evaluating Technosphere® Insulin Inhalation Powder and MedTone™ Inhaler for Type 2 Diabetes Mellitus. Completed, enrolled 229 participants across 40 sites in 4 countries.
Detailed Summary
Safety Follow-Up Trial to PDC-INS-0008 and MKC-TI-005
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesBulgaria, Czechia, Germany, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2004
Primary CompletionJun 2008
First PostedSep 2008
Study CompletionOct 2008
TodayJul 2026
First PostedSep 18, 2008
Enrollment StartMay 1, 2004
Primary CompletionJun 1, 2008
Study CompletionOct 1, 2008
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 17.8 years ago
Interventions
Technosphere® Insulin Inhalation Powder and MedTone™ Inhalerdrug
Inhalation starting at 15, 30, or 60U doses and can be titrated up or down by 15U to a minimum of 15U or a maximum of 90U